Merck & Co. Inc. (MRK) turns bearish with loss of -0.38 points

Merck & Co. Inc. (NYSE: MRK) is -6.25% lower on its value in year-to-date trading and has touched a low of $65.25 and a high of $92.64 in the current 52-week trading range. The MRK stock was last observed hovering at around $85.65 in the last trading session, with the day’s loss setting it -0.38% off its average median price target of $96.00 for the next 12 months. It is also 20.31% off the consensus price target high of $107.00 offered by 18 analysts, but current levels are -1.51% lower than the price target low of $84.00 for the same period.

Currently trading at $85.27, the stock is 2.00% and 6.19% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.55 million and changing -0.44% at the moment leaves the stock 4.05% off its SMA200. MRK registered -1.39% loss for a year compared to 6-month gain of 7.76%. The firm has a 50-day simple moving average (SMA 50) of $81.59 and a 200-day simple moving average (SMA200) of $79.15.

The stock witnessed a 6.27% loss in the last 1 month and extending the period to 3 months gives it a 5.48%, and is -0.18% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.16% over the week and 1.48% over the month.

Merck & Co. Inc. (MRK) has around 71000 employees, a market worth around $216.10B and $47.19B in sales. Current P/E ratio is 20.66 and Fwd P/E is 13.40. Profit margin for the company is 22.20%. Distance from 52-week low is 30.68% and -7.96% from its 52-week high. The company has generated returns on investments over the last 12 months (19.20%).

Merck & Co. Inc. (MRK) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Merck & Co. Inc. (MRK) is a “Overweight”. 18 analysts offering their recommendations for the stock have an average rating of 1.90, where 4 rate it as a Hold and 2 think it is a “Overweight”. 12 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Merck & Co. Inc. is expected to release its quarterly report on 10/27/2020 and quarterly earnings per share for the current quarter are estimated at $1.41 with sales reaching $12.07B over the same period.The EPS is expected to grow by 58.90% this year, but quarterly earnings will post 2.50% year-over-year. Quarterly sales are estimated to shrink -2.60% in year-over-year returns.

Merck & Co. Inc. (MRK) Top Institutional Holders

3,208 institutions hold shares in Merck & Co. Inc. (MRK), with 1.92M shares held by insiders accounting for 0.08% while institutional investors hold 78.61% of the company’s shares. The shares outstanding are 2.53B, and float is at 2.53B with Short Float at 0.47%. Institutions hold 78.55% of the Float.

Merck & Co. Inc. (MRK) Insider Activity

A total of 32 insider transactions have happened at Merck & Co. Inc. (MRK) in the last six months, with sales accounting for 17 and purchases happening 15 times. The most recent transaction is an insider sale by Chattopadhyay Sanat, the company’s Exe V-P & Pres. MMD. SEC filings show that Chattopadhyay Sanat sold 10,380 shares of the company’s common stock on Aug 13 at a price of $83.01 per share for a total of $0.86 million. Following the sale, the insider now owns 67373.0 shares.

Merck & Co. Inc. disclosed in a document filed with the SEC on Aug 05 that Clyburn Frank (EVP, Chief Commercial Officer) sold a total of 18,876 shares of the company’s common stock. The trade occurred on Aug 05 and was made at $81.55 per share for $1.54 million. Following the transaction, the insider now directly holds 80763.0 shares of the MRK stock.

Still, SEC filings show that on Jul 17, Gerberding Julie L. (EVP Strat Comm, GI Pub Policy) disposed off 36,285 shares at an average price of $80.00 for $2.9 million. The insider now directly holds 26,577 shares of Merck & Co. Inc. (MRK).

Merck & Co. Inc. (MRK): Who are the competitors?

The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 31.35% up over the past 12 months. Sanofi (SNY) is 17.76% up on the 1-year trading charts. Short interest in the company’s stock has fallen -24.07% from the last report on Jul 14, 2020 to stand at a total of 14.64 million short shares sold with a short interest ratio of 1.51.